Product Description
Mechanisms of Action: ADRB3 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Overactive Bladder|Irritable Bowel Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02938507 |
VEL-1001 | P1 |
Completed |
Overactive Bladder |
2016-12-01 |
58% |
2019-05-01 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
NCT00427596 |
B3A106044 | P1 |
Completed |
Overactive Bladder |
2007-08-01 |
2019-03-21 |
Treatments |
|
NCT00501267 |
B3C109868 | P1 |
Completed |
Overactive Bladder |
2007-08-01 |
2019-03-21 |
Treatments |
|
NCT00401479 |
Study B3I106248 | P1 |
Completed |
Irritable Bowel Syndrome |
None |
2019-03-21 |
Treatments |
|
NCT03594058 |
VEL-2001 | P2 |
Completed |
Overactive Bladder |
2019-04-29 |
76% |
2019-05-08 |
Primary Completion Date|Treatments |
NCT03475706 |
VEL-2002 | P2 |
Completed |
Overactive Bladder |
2019-01-24 |
64% |
2019-03-22 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
2005-006118-17 |
2005-006118-17 | P2 |
Completed |
Irritable Bowel Syndrome |
2007-06-14 |
2022-03-12 |
Treatments |
|
2005-005431-97 |
2005-005431-97 | P2 |
Completed |
Overactive Bladder |
2007-03-07 |
2022-03-12 |
Treatments |
|
NCT00343486 |
B3P104833 | P2 |
Completed |
Overactive Bladder |
None |
2019-03-21 |
Treatments |
|
NCT00394186 |
B3I105940 | P2 |
Completed |
Irritable Bowel Syndrome |
None |
2019-03-21 |
Treatments |